The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome

Amanda McBride; Sarah Houtmann; Lindsay Wilde; Carlos Vigil; Christine M. Eischen; Margaret Kasner; Neil Palmisiano

doi:10.3389/fonc.2019.00192

The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome

Amanda McBride, Sarah Houtmann, Lindsay Wilde, Carlos Vigil, Christine M. Eischen, Margaret Kasner, Neil Palmisiano^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.

Original language	English (US)
Article number	192
Journal	Frontiers in Oncology
Volume	9
Issue number	MAR
DOIs	https://doi.org/10.3389/fonc.2019.00192
State	Published - 2019
Externally published	Yes

Keywords

ALL
AML
BCL-2
Intrinsic apoptosis
MDS
Venetoclax

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2019.00192

Cite this

@article{686d29c75cbb411a9674e963262b459b,

title = "The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome",

abstract = "Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.",

keywords = "ALL, AML, BCL-2, Intrinsic apoptosis, MDS, Venetoclax",

author = "Amanda McBride and Sarah Houtmann and Lindsay Wilde and Carlos Vigil and Eischen, {Christine M.} and Margaret Kasner and Neil Palmisiano",

note = "Funding Information: Cancer Center Support Grant 5P30CA056036-17. Funding Information: Conflict of Interest Statement: CE and NP receive research funding from AbbVie. Publisher Copyright: Copyright {\textcopyright} 2019 McBride, Houtmann, Wilde, Vigil, Eischen, Kasner and Palmisiano.",

year = "2019",

doi = "10.3389/fonc.2019.00192",

language = "English (US)",

volume = "9",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

number = "MAR",

}

TY - JOUR

T1 - The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome

AU - McBride, Amanda

AU - Houtmann, Sarah

AU - Wilde, Lindsay

AU - Vigil, Carlos

AU - Eischen, Christine M.

AU - Kasner, Margaret

AU - Palmisiano, Neil

N1 - Funding Information: Cancer Center Support Grant 5P30CA056036-17. Funding Information: Conflict of Interest Statement: CE and NP receive research funding from AbbVie. Publisher Copyright: Copyright © 2019 McBride, Houtmann, Wilde, Vigil, Eischen, Kasner and Palmisiano.

PY - 2019

Y1 - 2019

N2 - Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.

AB - Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.

KW - ALL

KW - AML

KW - BCL-2

KW - Intrinsic apoptosis

KW - MDS

KW - Venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85066619336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066619336&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00192

DO - 10.3389/fonc.2019.00192

M3 - Review article

C2 - 30972300

AN - SCOPUS:85066619336

SN - 2234-943X

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

IS - MAR

M1 - 192

ER -

The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this